Novo Holdings Acquires Altasciences from Audax Private Equity
February 22, 2021
Novo Holdings has agreed to acquire Altasciences, a Laval, Canada–headquartered contract research and CDMO services provider, from Audax Private Equity. Altasciences— which operates six facilities across the U.S. and Canada and employs over 1,300 people—will remain led by CEO Chris Perkin and is expected to continue expanding domestically and internationally under Novo Holdings' ownership.
- Buyers
- Novo Holdings A/S
- Targets
- Altasciences
- Sellers
- Audax Private Equity
- Industry
- Healthcare Services
- Location
- Quebec, Canada
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Altasciences Acquires Alliance Contract Pharma
February 27, 2020
Pharmaceuticals
Altasciences, a mid-size contract research organization based in Laval, Quebec, has acquired Alliance Contract Pharma to add small-molecule contract manufacturing and analytical services, including commercial manufacturing, GMP warehouse storage, and clinical supply distribution. The acquisition expands Altasciences' integrated early‑phase drug development offering by adding manufacturing and analytical capabilities to its preclinical, clinical, and bioanalytical services.
-
Altasciences Acquires Sinclair Research
January 4, 2022
Healthcare Services
Altasciences completed the acquisition of Sinclair Research, a Midwest-based preclinical CRO, expanding its U.S. preclinical footprint and adding capacity and toxicology expertise. The deal brings Sinclair’s over-80-animal-room capabilities into Altasciences’ integrated CRO/CDMO platform to better support biopharmaceutical, animal health, and medical device development programs.
-
Novo Integrated Sciences / Novo Healthnet Acquire Acenzia Inc.
June 29, 2021
Pharmaceuticals
Novo Integrated Sciences, through its wholly owned subsidiary Novo Healthnet Limited, completed the acquisition of Acenzia Inc., a Windsor, Ontario-based nutraceutical manufacturer and diagnostics developer. The all-share transaction closed on June 24, 2021 and is valued at $14,884,039; Novo said the purchase will give it direct control of development, manufacturing and distribution of wellness products and personalized diagnostics.
-
Sygnature Discovery Acquires NuChem Sciences
August 1, 2023
Biotechnology
UK-based integrated drug discovery CRO Sygnature Discovery has acquired Montreal-headquartered NuChem Sciences, one of North America's largest discovery contract research organisations. The deal expands Sygnature's global footprint and capabilities in medicinal chemistry, DMPK, structural biology and in vitro/in vivo pharmacology, strengthening its position in the North American market.
-
NuChem Sciences Acquires IniXium
October 31, 2022
Biotechnology
Montreal-based contract research organization NuChem Sciences has acquired IniXium of Laval, Québec, with investment support from the Fonds de solidarité FTQ. The deal expands NuChem's structural biology and recombinant protein production capabilities—integrating IniXium's crystallography and fragment screening expertise into NuChem's drug-discovery services.
-
Rocscience Inc. Acquires NovoTech Software
October 6, 2021
Software
Rocscience Inc., a Toronto-based developer of geotechnical engineering software, has acquired Vancouver-based NovoTech Software. The deal expands Rocscience's geotechnical product capabilities and brings NovoTech's CTO and web application team into Rocscience while NovoTech continues to operate under its name in the near term.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.